Through the acquisition, Crown will expand its portfolio of in vitro services, including integration of OcellO's high content imaging into Crown's in vitro and in vivo screening and immunotherapy assessment services.

The acquisition establishes CrownBio as the only global source licensed to offer customers specialized Hubrecht organoid technology (HUB) for drug development programs.

Under the terms of the acquisition, Leo Price, PhD, CEO and chief scientific officer at OcellO, will join Crown as senior vice president of in vitro to lead the company's in vitro business in the U.S. and Europe.

Financial terms of the acquisition were not disclosed.

Charles River, Cypre collaborate on in vitro services
Charles River Laboratories is joining forces with Cypre to advance the understanding of the tumor microenvironment and predict therapeutic efficacy. Charles...